A detailed history of Charles Schwab Investment Management Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 380,583 shares of ABUS stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
380,583
Previous 339,215 12.2%
Holding current value
$1.5 Million
Previous $875,000 34.4%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$2.52 - $3.63 $104,247 - $150,165
41,368 Added 12.2%
380,583 $1.18 Million
Q1 2024

May 08, 2024

SELL
$2.26 - $2.92 $22,923 - $29,617
-10,143 Reduced 2.9%
339,215 $875,000
Q3 2023

Nov 08, 2023

BUY
$1.9 - $2.27 $25,241 - $30,156
13,285 Added 3.95%
349,358 $709,000
Q2 2023

Aug 09, 2023

BUY
$2.24 - $3.06 $60,712 - $82,938
27,104 Added 8.77%
336,073 $772,000
Q1 2023

May 11, 2023

BUY
$2.23 - $3.1 $8,226 - $11,435
3,689 Added 1.21%
308,969 $936,000
Q4 2022

Feb 13, 2023

BUY
$1.91 - $2.85 $34,114 - $50,903
17,861 Added 6.21%
305,280 $711,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $1,005 - $1,540
-535 Reduced 0.19%
287,419 $549,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $95,517 - $152,923
48,241 Added 20.12%
287,954 $781,000
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $73,417 - $120,745
30,338 Added 14.49%
239,713 $715,000
Q3 2021

Nov 16, 2021

BUY
$2.65 - $4.62 $60,703 - $105,830
22,907 Added 12.28%
209,375 $899,000
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $413,890 - $581,101
165,556 Added 791.68%
186,468 $565,000
Q4 2020

Feb 16, 2021

SELL
$2.76 - $4.97 $33,120 - $59,640
-12,000 Reduced 36.46%
20,912 $75,000
Q3 2020

Nov 13, 2020

BUY
$1.75 - $6.2 $57,596 - $204,054
32,912 New
32,912 $104,000
Q2 2019

Aug 09, 2019

SELL
$1.46 - $4.44 $96,214 - $292,596
-65,900 Closed
0 $0
Q2 2018

Aug 08, 2018

BUY
$5.0 - $7.35 $329,500 - $484,365
65,900 New
65,900 $482,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $591M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.